Table 4 Comparison of the characteristics of postmenopausal patients with sarcomas and leiomyomas who underwent surgery for uterine mesenchymal tumors
From: Analysis of uterine corporeal mesenchymal tumors occurring after menopause
Total | Sarcoma | Benign | p-value | ||||
|---|---|---|---|---|---|---|---|
Number of patients | 40 | 100% | 11 | 27.5% | 29 | 72.5% | |
Age(yr) | 62.5 | (50–81) | 66 | (50–80) | 60 | (51–81) | 0.12 |
Age at menopause(yr) | 51 | (49–57) | 52 | (49–55) | 51 | (49–57) | 0.523 |
BMI | 22.6 | (15.4–39.4) | 22.4 | (19–27.8) | 22.6 | (15.4–39.4) | 0.654 |
Tumor size(cm) | 10 | (2.6–30) | 10 | (6–30) | 9 | (2.6–24) | 0.2 |
Serum CA125(U/ml) | 13 | (5.6–234.1) | 18.3 | (11–234.1) | 11.5 | (5.6–44.2) | 0.054 |
Serum CA19–9(U/ml) | 6.4 | (1.2–303) | 6 | (2–19.9) | 6.5 | (1.2–303) | 0.94 |
Serum CEA(ng/ml) | 1.45 | (0.4–6.3) | 1.5 | (0.5–4.9) | 1.4 | (0.4–6.3) | 0.598 |
Serum LDH(IU/l) | 203 | (125–629) | 225 | (156–629) | 202 | (125–300) | 0.08 |
Abnormal bleeding | 7 | 17.5% | 3 | 27.3% | 4 | 13.8% | 0.399 |
Abnormal signal on MRI | 22 | 55% | 11 | 100% | 11 | 37.9% | < 0.001* |